RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

Background: passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2. Methods: we conducted a double-blind, randomized, placebo-controlled trial to assess effica...

Full description

Bibliographic Details
Main Authors: Gustavo Lopardo, Waldo H. Belloso, Esteban Nannini, Mariana Colonna, Santiago Sanguineti, Vanesa Zylberman, Luciana Muñoz, Martín Dobarro, Gabriel Lebersztein, Javier Farina, Gabriela Vidiella, Anselmo Bertetti, Favio Crudo, Maria Fernanda Alzogaray, Laura Barcelona, Ricardo Teijeiro, Sandra Lambert, Darío Scublinsky, Marisa Iacono, Vanina Stanek, Rubén Solari, Pablo Cruz, Marcelo Martín Casas, Lorena Abusamra, Héctor Lucas Luciardi, Alberto Cremona, Diego Caruso, Bernardo de Miguel, Santiago Perez Lloret, Susana Millán, Yael Kilstein, Ana Pereiro, Omar Sued, Pedro Cahn, Linus Spatz, Fernando Goldbaum
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021001231

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021001231

Similar Items